A constant source of frustration for drug manufacturers shipping products to the United States is mandates from FDA and U.S Customs and Border Protection (CBP) for import of medicinal products. These requirements affect not only finished product, but also everything from active ingredients to devices used in support of clinical trials.
This course addresses the 2016 implementation of FDA’s and CBP’s new entry information program — the Automated Commercial Environment (ACE) — which applies to the initial importer, the customs broker, and the foreign firm associated with an imported product’s entry into the U.S. Importers and brokers currently struggle to use the correct FDA information codes, and failure to do so may cause the entry to be detained and monetary fines. The ACE procedures, entry status information, and simplification of entry documentation can provide significant benefits to the parties involved, but the importer and broker must understand the operational function of the ACE program to use it successfully.
Join our online training course, where you will learn:
- ACE implementation of FDA and CBP import requirements
- Information and data entry requirements
- How the ACE program logistically functions for U.S. import brokers, initial importers, and foreign exporters
- The benefits of the ACE program for importers and brokers who interact with CBP and FDA